HK Stock Market Move | CLOVER BIO-B(02197) up by over 7% again, Clover Biopharmaceuticals' respiratory syncytial virus (RSV) vaccine Phase II clinical trial shows promising progress.

CLOVER BIO-B (02197) surged more than 7%, rising 5.21% to HK$3.03 as of the time of writing, with a trading volume of HK$30.6497 million. On the news front, Clover Biopharmaceuticals announced earlier that the recruitment for the Australian Phase II clinical trials of the group's proprietary respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) combination vaccine candidates SCB-1022 and SCB-1033 has been completed. Preliminary clinical results are expected to be announced in the third quarter of 2026. In addition, Clover Biopharmaceuticals recently reached a settlement with the global Vaccine Alliance. Under the settlement agreement, the company is required to make a one-time upfront payment of $7 million and bear deferred payments every six months, linked to future cash income, with a total payment cap in the mid-tens of millions of dollars, significantly reducing the claim previously made by Gavi for $224 million.